HT
ITCI

Headlands Technologies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Headlands Technologies’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,637
Closed -$876K – 1609
2025
Q1 		$876K Sell
6,637
-12,428
-65% -$1.55M 0.1% 208
2024
Q4 		$1.59M Buy
19,065
+2,883
+18% +$237K 0.16% 151
2024
Q3 		$1.18M Sell
16,182
-9,300
-36% -$699K 0.14% 165
2024
Q2 		$1.75M Buy
25,482
+25,014
+5,345% +$1.73M 0.19% 108
2024
Q1 		$32.4K Buy
+468
New +$32.2K 0.01% 809
2023
Q4 		– Sell
-4,027
Closed -$210K – 1367
2023
Q3 		$210K Buy
4,027
+1,982
+97% +$115K 0.1% 193
2023
Q2 		$129K Buy
+2,045
New +$127K 0.04% 351

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Headlands Technologies's ITCI Position: Q2 2025 in Review

Headlands Technologies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 6,637 shares — an estimated $876K sold.

Headlands Technologies first reported a position in ITCI in Q2 2023 and held it in 7 quarters. The position peaked at $1.75M in Q2 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Headlands Technologies reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Headlands Technologies sold 6,637 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $876K.
  • Headlands Technologies first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 7 quarters.
  • Headlands Technologies's Intra-Cellular Therapies Inc. position peaked at $1.75M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Headlands Technologies's 13F filing for Q2 2025, filed 14 Aug 2025.